 Connection
Marc Bonaca to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Marc Bonaca has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.411 |
|
|
|
-
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
Score: 0.164
-
Canonico ME, Hsia J, Guthrie NL, Simmons M, Mehta P, Lupinacci P, Edwards K, Mosesso K, Gearhart M, Skuban A, Bonaca MP, Berman MA. Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. Clin Cardiol. 2022 Aug; 45(8):850-856.
Score: 0.045
-
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thromb Haemost. 2021 12; 121(12):1684-1695.
Score: 0.042
-
Åstrand M, Amilon C, Röshammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamrén B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol. 2019 02; 85(2):413-421.
Score: 0.035
-
Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD. DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018 05; 20(5):1102-1110.
Score: 0.033
-
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 06; 200:83-89.
Score: 0.033
-
Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 05; 199:83-91.
Score: 0.033
-
Bansilal S, Bonaca MP, Sabatine MS. Ticagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013 Nov; 11(11):1473-84.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|